

Katharina T Prochazka

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5842097/publications.pdf>

Version: 2024-02-01

16
papers

200
citations

1684188

5
h-index

1125743

13
g-index

16
all docs

16
docs citations

16
times ranked

351
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical implications of subclonal <i>TP53</i> mutations in acute myeloid leukemia. <i>Haematologica</i> , 2019, 104, 516-523.	3.5	65
2	Immune Regulatory Processes of the Tumor Microenvironment under Malignant Conditions. <i>International Journal of Molecular Sciences</i> , 2021, 22, 13311.	4.1	54
3	NR4A3 Suppresses Lymphomagenesis through Induction of Proapoptotic Genes. <i>Cancer Research</i> , 2017, 77, 2375-2386.	0.9	24
4	Immunohistochemistry for <i>c-myc</i> and <i>bcl-2</i> overexpression improves risk stratification in primary central nervous system lymphoma. <i>Hematological Oncology</i> , 2020, 38, 277-283.	1.7	19
5	The CXCR4-CXCL12-Axis Is of Prognostic Relevance in DLBCL and Its Antagonists Exert Pro-Apoptotic Effects In Vitro. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4740.	4.1	14
6	Vinorelbine as substitute for vincristine in patients with diffuse large B cell lymphoma and vincristine-induced neuropathy. <i>Supportive Care in Cancer</i> , 2021, 29, 5197-5207.	2.2	6
7	Immunohistochemical double hit score enhances <i>NCCN</i> <i>IPI</i> and is associated with detrimental outcomes in refractory or relapsing patients with diffuse large B cell lymphoma. <i>British Journal of Haematology</i> , 2018, 183, 142-146.	2.5	4
8	Cytoplasmic location of NR4A1 in aggressive lymphomas is associated with a favourable cancer specific survival. <i>Scientific Reports</i> , 2018, 8, 14528.	3.3	4
9	Expression profile of translation initiation factor eIF2B5 in diffuse large B-cell lymphoma and its correlation to clinical outcome. <i>Blood Cancer Journal</i> , 2018, 8, 79.	6.2	4
10	The Role of Immunohistochemical Overexpression of p53 as Adverse Prognostic Factor in Primary Testicular Diffuse Large B Cell Lymphoma. <i>Pathology and Oncology Research</i> , 2020, 26, 2831-2833.	1.9	2
11	Chronic lymphocytic leukaemia—what is new and notable in 2021, with a special focus on COVID-19. <i>Memo - Magazine of European Medical Oncology</i> , 2021, 14, 224-227.	0.5	1
12	Deregulated CXCR4-CXCL12 Signaling Impacts on the Pathogenesis of DLBCL. <i>Blood</i> , 2019, 134, 1519-1519.	1.4	1
13	Impact of the microenvironment on the pathogenesis of mucosa-associated lymphoid tissue lymphomas. <i>World Journal of Gastrointestinal Oncology</i> , 2022, 14, 153-162.	2.0	1
14	Bcl2 inhibitor venetoclax + Anti-CD20: what do deep remissions mean?. <i>Memo - Magazine of European Medical Oncology</i> , 2022, 15, 45-48.	0.5	1
15	Prognostic Value of Baseline and Interim Positron Emission Tomography Markers in Diffuse Large B-cell Lymphoma Patients: A Real-world Perspective. <i>HemaSphere</i> , 2021, 5, e621.	2.7	0
16	Impact of TP53 Mutated Subclones in Acute Myeloid Leukemia. <i>Blood</i> , 2018, 132, 1483-1483.	1.4	0